Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Dec 11, 2015

Cepheid's BCR-ABL Ultra

Cepheid has begun shipping the CE-IVD marked Xpert BCR-ABL Ultra test to quantitate mRNA transcripts in patients with chronic myelogenous leukemia undergoing tyrosine kinase inhibitor treatment. The assay is an updated version of the Xpert BCR-ABL Monitor test that provides increased sensitivity, the firm said. It is aligned to the International Scale on a lot-to-lot basis, increasing reliability of comparisons between labs, and uses the Cepheid GeneXpert system to deliver results in less than two and a half hours.

Bioline JetSeq DNA Library Preparation Kit

Bioline, a subsidiary of Meridian Bioscience, has launched the JetSeq DNA library preparation kit. The new kit uses highly optimized enzymes and buffers, developed in collaboration with Oxford Gene Technology, to enable the preparation of the highest quality NGS sequencing-ready, adapter-ligated DNA for Illumina's Next-Generation Sequencers. The technology uses a combination of end repair and A-tailing followed by direct ligation of the adapters, thus reducing hands-on time and making the process faster and easier to use. Additionally, the technology reduces the number of required clean-up steps, significantly improving the yield and quality of sequence-ready libraries and reducing the amount of DNA required, the company said. 

NeoLAB Solid Tumor Monitor and BTK Inhibitor Acquired Resistance Test

NeoGenomics has launched the NeoLAB Solid Tumor Monitor and NeoLAB Bruton Tyrosine Kinase (BTK) Inhibitor Acquired Resistance test. Each new test uses cell-free DNA from peripheral blood plasma to quantify and track genomic abnormalities in the tumors of cancer patients. Resistance to BTK inhibitors is associated with mutations in the BTK and PLCG2 genes. The test is capable of detecting mutations in these two genes prior to tissue or cell-based testing. The test can be used to monitor patients treated with BTK inhibitors, especially in chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma, and to alert physicians to mutations in BTK and PLCG2 that may indicate early resistance to BTK inhibitor treatment.

For more new products and services, please visit the New Products page on our website.